Amid a rising uproar over drug prices, UnitedHealthcare said Tuesday it will pass along to consumers in employer-based plans the rebates it receives from pharmaceutical companies.
Amid a rising uproar over drug prices, UnitedHealthcare said Tuesday it will pass along to consumers in employer-based plans the rebates it receives from pharmaceutical companies.
The health insurer, whose parent company owns the pharmacy benefit plan OptumRx, said it will expand pharmacy discounts to millions of its plan participants when they fill prescriptions through retail pharmacies or home delivery. The discounts will apply to over 7 million people enrolled in commercial group benefit plans. Discounts will come at the pharmacy counter at the time of purchase beginning on January 1, 2019.
The savings will apply to plan participants who are filling a prescription for a drug where the manufacturer provides a rebate.
In a statement, HHS Secretary Alex Azar praised the move.
“Today’s announcement by UnitedHealthcare is a prime example of the type of movement toward transparency and lower drug prices for millions of patients that the Trump administration is championing,” Azar said. “Empowering patients and providers with the information and control to put them in the driver’s seat is a key part of our strategy at the Department of Health and Human Services to bring down the price of drugs and make healthcare more affordable. We are already seeing clear momentum toward the type of innovation in the private-sector that will be an important part of the value-based transformation that is coming to America’s healthcare system.”
Dan Schumacher, the president of UnitedHealthcare, told The New York Times that those in plans with high deductibles who buy drugs with large rebates will see the greatest savings.
The Trump administration has previously suggested that the same rebates could be passed on to those in Medicare programs.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
ACA Dependent Coverage Extension and Young Adults’ Substance-Associated ED Visits
September 15th 2025This study examines the impact of the Affordable Care Act (ACA) on substance-associated emergency department (ED) visits among young adults, revealing reduced alcohol-associated visits but unchanged opioid-associated visits.
Read More